Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aromatase inhibitors: current status

N K Ibrahim1, A U Buzdar

  • 1Department of Breast and Gynecology Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

American Journal of Clinical Oncology
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Breast cancer research and treatment·2016
Same author

Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.

PloS one·2016
Same author

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Which threshold for ER positivity? a retrospective study based on 9639 patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same journal

Upper Extremity Lymphedema​​​: Performance of a Risk Prediction Model in Women Undergoing Surgery for Breast Cancer.

American journal of clinical oncology·2026
Same journal

Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for the Use of Radiation in the Prevention and Treatment of Heterotopic Ossification (HO).

American journal of clinical oncology·2026
Same journal

Stereotactic Body Radiation Therapy Combined With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Comprehensive Single-Arm Meta-Analysis Approach.

American journal of clinical oncology·2026
Same journal

Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States.

American journal of clinical oncology·2026
Same journal

Early Versus Delayed Pancreatic Enzyme Replacement Therapy After Pancreatic Cancer Surgery: A Real-World Cohort Study.

American journal of clinical oncology·2026
Same journal

Early Economic and Patient-Centered Outcomes Before Spine Metastases Radiation Therapy From an Ongoing Phase II Randomized Controlled Trial.

American journal of clinical oncology·2026
See all related articles

Newer aromatase inhibitors show significant antitumor activity for metastatic breast cancer treatment. These agents may offer a better therapeutic index compared to existing drugs.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Estrogen is a key driver in many breast cancers.
  • Aromatase inhibitors block estrogen production, a crucial therapeutic strategy.

Purpose of the Study:

  • To review aromatase inhibitors for metastatic breast cancer.
  • Focus on newer agents and their development.

Main Methods:

  • Literature review of English articles from the past 5 years.
  • Searches conducted using Med-Line and Cancer-Line databases.

Main Results:

  • Aminoglutethimide identified as a prototype aromatase inhibitor.
  • Newer agents demonstrate significant antitumor activity.
  • Evaluation of structure, chemistry, pharmacology, pharmacokinetics, and antitumor effects.

Related Experiment Videos

Conclusions:

  • New aromatase inhibitors possess substantial antitumor activity in breast cancer.
  • These novel agents may provide an improved therapeutic index over current treatments.